» Articles » PMID: 30684003

Deciphering Myeloid-derived Suppressor Cells: Isolation and Markers in Humans, Mice and Non-human Primates

Abstract

In cancer, infection and inflammation, the immune system's function can be dysregulated. Instead of fighting disease, immune cells may increase pathology and suppress host-protective immune responses. Myeloid cells show high plasticity and adapt to changing conditions and pathological challenges. Despite their relevance in disease pathophysiology, the identity, heterogeneity and biology of myeloid cells is still poorly understood. We will focus on phenotypical and functional markers of one of the key myeloid regulatory subtypes, the myeloid derived suppressor cells (MDSC), in humans, mice and non-human primates. Technical issues regarding the isolation of the cells from tissues and blood, timing and sample handling of MDSC will be detailed. Localization of MDSC in a tissue context is of crucial importance and immunohistochemistry approaches for this purpose are discussed. A minimal antibody panel for MDSC research is provided as part of the Mye-EUNITER COST action. Strategies for the identification of additional markers applying state of the art technologies such as mass cytometry will be highlighted. Such marker sets can be used to study MDSC phenotypes across tissues, diseases as well as species and will be crucial to accelerate MDSC research in health and disease.

Citing Articles

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.

Bakker N, Garner H, van Dyk E, Champanhet E, Klaver C, Duijst M NPJ Breast Cancer. 2025; 11(1):5.

PMID: 39843922 PMC: 11754814. DOI: 10.1038/s41523-025-00721-2.


Circulating CD3CD8 T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer.

Chen H, Chen Y, Chung W, Loh Z, Lee K, Hsu H Cancer Med. 2025; 14(1):e70547.

PMID: 39749673 PMC: 11696249. DOI: 10.1002/cam4.70547.


Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target.

Klein C, Mebroukine S, Madery M, Moisand A, Boyer T, Larmonier N Cells. 2024; 13(21.

PMID: 39513886 PMC: 11544784. DOI: 10.3390/cells13211779.


Lymphopenia in sepsis: a narrative review.

Wang Z, Zhang W, Chen L, Lu X, Tu Y Crit Care. 2024; 28(1):315.

PMID: 39304908 PMC: 11414153. DOI: 10.1186/s13054-024-05099-4.


TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION.

Restaino A, Ahmadi M, Nikpoor A, Walz A, Balood M, Eichwald T bioRxiv. 2024; .

PMID: 39253487 PMC: 11382997. DOI: 10.1101/2024.08.23.609450.


References
1.
Schmielau J, Finn O . Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001; 61(12):4756-60. View

2.
Bogdan C . Nitric oxide and the immune response. Nat Immunol. 2001; 2(10):907-16. DOI: 10.1038/ni1001-907. View

3.
Vasconcelos Z, Santos B, Costa E, Lima M, Tabak D, Bouzas L . T-lymphocyte function from peripheral blood stem-cell donors is inhibited by activated granulocytes. Cytotherapy. 2003; 5(4):336-45. DOI: 10.1080/14653240310002252. View

4.
Zea A, Rodriguez P, Atkins M, Hernandez C, Signoretti S, Zabaleta J . Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005; 65(8):3044-8. DOI: 10.1158/0008-5472.CAN-04-4505. View

5.
Munn D, Sharma M, Baban B, Harding H, Zhang Y, Ron D . GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22(5):633-42. DOI: 10.1016/j.immuni.2005.03.013. View